Brazil in the Global Regulatory Landscape
Brazil's medical device regulatory system — led by ANVISA — is one of the largest and most sophisticated in the Americas, and one of the most important markets for manufacturers seeking to expand beyond the EU, US, and other mature markets.
Brazil's position
| Feature | Detail |
|---|---|
| Market size | 6th largest medical device market globally (by value, est. 2025) |
| Regulatory authority | ANVISA (federal), state VISA, municipal VISA |
| IMDRF member | Yes — full voting member since 2020 |
| MERCOSUL member | Yes — founding member; medical device regulations harmonised with Argentina, Uruguay, Paraguay |
| ISO 13485 acceptance | Yes — accepted for foreign manufacturer GMP compliance |
| UDI implementation | In progress — aligned with IMDRF framework |
Key strengths of the Brazilian regulatory framework
- Risk-based classification aligned with IMDRF and MERCOSUL
- Online submission via Peticionamento Eletrônico
- 10-year registration validity
- Active participation in IMDRF working groups
- Growing alignment with ISO standards and international GCP
Key challenges
- Long review timelines for Class III/IV Registro (12–36 months)
- Portuguese language requirement for all labelling and submissions
- Three-tier regulatory system (federal + state + municipal) adds complexity
- Importer as registration holder model creates additional obligations for foreign manufacturers
- AFE requirement for all economic operators adds compliance cost
Official resources
Official sources
Verify all information against official ANVISA sources before making regulatory decisions.